The novel coronavirus SARS-CoV-2 pandemic has brought about an urgency to rapidly develop monoclonal antibodies (mAbs) that neutralize and inhibit this virus. These are the most readily manufacturable therapeutics that can be administered to prevent or treat COVID-19 disease. To meet this global challenge, scientists are now pursuing diverse approaches that integrate the use of either patient B cells, yeast or phage display with cell sorting, sequencing and advanced bioinformatics to advance therapeutic mAb discovery.
Join our free educational webinar with Dr. Naveen Suryadevara, Scientists at Vanderbilt Vaccine Center and Dr. Alon Wellner, Researcher at University of California, to learn about the approaches used by two scientific groups who have accelerated antibody discovery with these pipeline technologies.
Who should attend?
This webinar will provide insights to researchers who want to learn how integrated approaches can be implemented to support swift therapeutic mAb discovery and validation.
Certificate of attendance
All webinar participants can request a certificate of attendance and a learning outcomes summary document for continuing education purposes.
This webinar will run on Thursday, August 6, at:
SelectScience runs more than 10 webinars a month across various scientific topics, discover more of our upcoming webinars>>